Viking Therapeutics Inc. (VKTX)
$38.95
$1.08
(2.84%)
As on 25-Jun-2026 10:36EDT
Market cap
$3,527 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-71.6
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-4.2
-
Face value
--
-
Shares outstanding
116,105,643
10 Years Aggregate
CFO
$-270.79 Mln
EBITDA
$-346.12 Mln
Net Profit
$-375.21 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Viking Therapeutics (VKTX)
| 10.7 | 26.1 | 21.1 | 44.5 | 24.1 | 43.6 | 41.2 |
|
BSE Sensex
| -8.9 | 2.2 | 4.1 | -6.0 | 7.0 | 7.9 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Viking Therapeutics (VKTX)
| -12.6 | 114.9 | 98.0 | 104.3 | -18.3 | -29.8 | 4.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Viking Therapeutics (VKTX)
|
38.9 | 3,527.3 | 0.0 | -472.3 | -- | -77.8 | -- | 7.0 |
| 293.4 | 37,128.5 | 4,286.9 | 577.2 | 20.3 | 88.2 | 69.9 | 34.5 | |
| 243.1 | 15,136.9 | 867.5 | 506.6 | -0.6 | -- | 26.3 | 26.7 | |
| 53.1 | 13,047.8 | 2,375.5 | 833.4 | 41.5 | 40.7 | 17.2 | 6.7 | |
| 188.3 | 28,000.8 | 16,632.0 | 1,385.0 | 14.1 | 22.3 | 20.9 | 4.5 | |
| 512.9 | 11,660.4 | 1,132.5 | -309.4 | -25.0 | -52.9 | -- | 21.4 | |
| 531.4 | 13,143.2 | 2,678.3 | 460.4 | 21.3 | 103.2 | 29 | 22.0 | |
| 628.3 | 63,945.5 | 14,919.6 | 4,423.4 | 34.9 | 14.2 | 14.9 | 2.0 | |
| 551.0 | 22,776.5 | 3,169.8 | 1,287.4 | 51.3 | 20.6 | 19.8 | 3.9 | |
| 483.1 | 114,626.1 | 12,255.1 | 4,338.3 | 42.2 | 23.7 | 26.8 | 5.9 |
Shareholding Pattern
View DetailsAbout Viking Therapeutics (VKTX)
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective... agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. Read more
-
President, CEO & Director
Dr. Brian Lian Ph.D.
-
President, CEO & Director
Dr. Brian Lian Ph.D.
-
Headquarters
San Diego, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Viking Therapeutics (VKTX)
What is the current share price of Viking Therapeutics Inc (VKTX) Today?
The share price of Viking Therapeutics Inc (VKTX) is $38.95 (NASDAQ) as of 25-Jun-2026 10:36 EDT. Viking Therapeutics Inc (VKTX) has given a return of 24.05% in the last 3 years.
What is the current PB & PE ratio of Viking Therapeutics Inc (VKTX)?
Since, TTM earnings of Viking Therapeutics Inc (VKTX) is negative, P/E ratio is not available.
The P/B ratio of Viking Therapeutics Inc (VKTX) is 7.03 times as on 18-Jun-2026, a 63 premium to its peers’ median range of 4.30 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-11.05
|
6.22
|
|
2024
|
-39.89
|
4.98
|
|
2023
|
-20.37
|
5.02
|
|
2022
|
-10.51
|
4.98
|
|
2021
|
-6.44
|
1.75
|
What is the 52 Week High and Low of Viking Therapeutics Inc (VKTX)?
The 52-week high and low of Viking Therapeutics Inc (VKTX) are Rs 43.15 and Rs 22.96 as of 25-Jun-2026.
What is the market cap of Viking Therapeutics Inc (VKTX)?
Viking Therapeutics Inc (VKTX) has a market capitalisation of $ 3,527 Mln as on 18-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Viking Therapeutics Inc (VKTX)?
Before investing in Viking Therapeutics Inc (VKTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.